HRP20020247B1 - Antiviral compositions - Google Patents
Antiviral compositionsInfo
- Publication number
- HRP20020247B1 HRP20020247B1 HR20020247A HRP20020247A HRP20020247B1 HR P20020247 B1 HRP20020247 B1 HR P20020247B1 HR 20020247 A HR20020247 A HR 20020247A HR P20020247 A HRP20020247 A HR P20020247A HR P20020247 B1 HRP20020247 B1 HR P20020247B1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- amino
- substituted
- alkyloxycarbonyl
- alkyloxy
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- -1 cyano, amino, imino, aminocarbonyl Chemical group 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 4
- 125000001041 indolyl group Chemical group 0.000 abstract 4
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007962 solid dispersion Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99203128 | 1999-09-24 | ||
PCT/EP2000/008522 WO2001022938A1 (en) | 1999-09-24 | 2000-08-31 | Antiviral compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20020247A2 HRP20020247A2 (en) | 2004-04-30 |
HRP20020247B1 true HRP20020247B1 (en) | 2011-02-28 |
Family
ID=8240674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20020247A HRP20020247B1 (en) | 1999-09-24 | 2002-03-22 | Antiviral compositions |
Country Status (35)
Country | Link |
---|---|
US (4) | US7241458B1 (bg) |
EP (1) | EP1225874B1 (bg) |
JP (1) | JP4919566B2 (bg) |
KR (2) | KR100785360B1 (bg) |
CN (1) | CN1234347C (bg) |
AP (1) | AP1639A (bg) |
AT (1) | ATE316781T1 (bg) |
AU (2) | AU775360B2 (bg) |
BG (1) | BG65754B1 (bg) |
BR (1) | BRPI0014271B1 (bg) |
CA (1) | CA2384188C (bg) |
CY (1) | CY1105268T1 (bg) |
CZ (1) | CZ300712B6 (bg) |
DE (1) | DE60025837T2 (bg) |
DK (1) | DK1225874T3 (bg) |
EA (1) | EA005423B1 (bg) |
EE (1) | EE04991B1 (bg) |
ES (1) | ES2258018T3 (bg) |
HK (1) | HK1048768B (bg) |
HR (1) | HRP20020247B1 (bg) |
HU (1) | HU228449B1 (bg) |
IL (1) | IL148801A0 (bg) |
IS (1) | IS2567B (bg) |
MX (1) | MXPA02003182A (bg) |
NO (1) | NO333358B1 (bg) |
NZ (1) | NZ517025A (bg) |
OA (1) | OA12029A (bg) |
PL (1) | PL207590B1 (bg) |
PT (1) | PT1225874E (bg) |
SI (1) | SI1225874T1 (bg) |
SK (1) | SK285240B6 (bg) |
TR (1) | TR200200763T2 (bg) |
UA (1) | UA74797C2 (bg) |
WO (1) | WO2001022938A1 (bg) |
ZA (1) | ZA200202289B (bg) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE396978T1 (de) | 1999-10-07 | 2008-06-15 | Amgen Inc | Triazin-kinase-hemmer |
ATE329579T1 (de) | 1999-11-12 | 2006-07-15 | Abbott Lab | Feste dispersion mit ritonavir, fenofibrat oder griseofulvin |
US20030004174A9 (en) | 2000-02-17 | 2003-01-02 | Armistead David M. | Kinase inhibitors |
DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
JP2004526714A (ja) | 2001-02-27 | 2004-09-02 | テバ ファーマシューティカル インダストリーズ リミティド | ラモトリジンの新しい結晶形およびそれらの調製方法 |
CA2450957A1 (en) | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
US8101629B2 (en) | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
ES2314106T3 (es) | 2001-10-17 | 2009-03-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG | Derivados de pirimidina, agentes farmaceuticos que contiene dichos compuestos, uso y metodo para su obtencion. |
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
CN1625410A (zh) | 2002-02-05 | 2005-06-08 | 山之内制药株式会社 | 2,4,6-三氨基-1,3,5-三嗪衍生物 |
AU2003234240A1 (en) * | 2002-04-23 | 2003-11-10 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing lamotrigine particles of defined morphology |
AR039540A1 (es) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
WO2004000318A2 (en) | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
CN1678321A (zh) | 2002-07-29 | 2005-10-05 | 里格尔药品股份有限公司 | 用2,4-嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
KR101140785B1 (ko) | 2002-08-09 | 2012-05-03 | 얀센 파마슈티카 엔.브이. | 4-〔〔4-〔〔4-(2-시아노에테닐)-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법 |
CA2499550C (en) * | 2002-09-20 | 2013-10-15 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
WO2004048343A1 (en) * | 2002-11-28 | 2004-06-10 | Schering Aktiengesellschaft | Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
EA011009B1 (ru) | 2003-01-14 | 2008-12-30 | Арена Фармасьютикалз Инк. | 1,2,3-тризамещённые арильные и гетероарильные производные в качестве модуляторов метаболизма и профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия |
KR20110132482A (ko) * | 2003-02-07 | 2011-12-07 | 얀센 파마슈티카 엔.브이. | Hiv 감염 예방용 피리미딘 유도체 |
CL2004000306A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
CN1822843B (zh) | 2003-07-17 | 2010-04-28 | 泰博特克药品有限公司 | 制备含有抗病毒药物颗粒的方法 |
BRPI0413018B8 (pt) | 2003-07-30 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, e, uso de um composto |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
BRPI0415398A (pt) | 2003-10-17 | 2006-12-19 | Astrazeneca Ab | composto, composição farmacêutica, processo para a preparação da mesma, uso de um composto, método de tratamento de cáncer, e, processo para preparação de um composto |
AU2005229331B2 (en) | 2004-03-05 | 2011-10-13 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as P2X3 and P2X2/3 antagonists |
TW200626139A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
CA2580844A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase |
BRPI0515489A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase |
BRPI0515483A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase |
BRPI0515505A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase |
AU2005286731A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
BRPI0515488A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados de heterocìclicos e seu uso como agentes terapêuticos |
WO2006068770A1 (en) | 2004-11-24 | 2006-06-29 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
EP2161275A1 (en) | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
DK1853588T3 (da) | 2005-02-16 | 2008-09-15 | Astrazeneca Ab | Kemiske forbindelser |
EP1853567B1 (en) * | 2005-02-18 | 2014-12-31 | Janssen R&D Ireland | Hiv inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives |
JP5118978B2 (ja) * | 2005-03-04 | 2013-01-16 | テイボテク・フアーマシユーチカルズ | Hiv阻害2−(4−シアノフェニル)−6−ヒドロキシルアミノピリミジン |
TW200710091A (en) | 2005-04-11 | 2007-03-16 | Tibotec Pharm Ltd | (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors |
MX2007014328A (es) | 2005-05-16 | 2008-02-12 | Astrazeneca Ab | Compuestos quimicos. |
EP1888537B1 (en) | 2005-05-26 | 2013-09-11 | Janssen R&D Ireland | Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino benzonitrile |
WO2007130075A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
CA2620129C (en) | 2005-09-01 | 2014-12-23 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
WO2007025900A1 (en) | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p3x2/3 modulators |
JP4850911B2 (ja) | 2005-09-01 | 2012-01-11 | エフ.ホフマン−ラ ロシュ アーゲー | P2x3およびp2x2/3モジュレーターとしてのジアミノピリミジン |
NZ567584A (en) | 2005-10-28 | 2011-08-26 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
JP2009514884A (ja) * | 2005-11-04 | 2009-04-09 | イーストマン ケミカル カンパニー | 難溶性医薬活性剤の投与のためのカルボキシアルキルセルロースエステル |
EP2029110B1 (en) * | 2006-06-06 | 2011-08-31 | Tibotec Pharmaceuticals | Process for preparing spray dried formulations of tmc125 |
PT2484346T (pt) | 2006-06-19 | 2017-04-26 | Alpharma Pharmaceuticals Llc | Composições farmacêuticas |
US20080233156A1 (en) * | 2006-10-11 | 2008-09-25 | Alpharma, Inc. | Pharmaceutical compositions |
US20100041687A1 (en) * | 2006-12-06 | 2010-02-18 | Thone Daniel Joseph Christiaan | Hydrobromide salt of an anti-hiv compound |
AR065720A1 (es) * | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
CN101784263B (zh) * | 2007-06-08 | 2012-11-07 | 贝林格尔.英格海姆国际有限公司 | 奈韦拉平的延长释放制剂 |
CN101790371A (zh) * | 2007-06-25 | 2010-07-28 | 泰博特克药品公司 | 包含达芦那韦和依曲韦林的组合制剂 |
US8410124B2 (en) | 2007-10-18 | 2013-04-02 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
US7989465B2 (en) * | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
US7982036B2 (en) * | 2007-10-19 | 2011-07-19 | Avila Therapeutics, Inc. | 4,6-disubstitued pyrimidines useful as kinase inhibitors |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
WO2009079521A1 (en) * | 2007-12-17 | 2009-06-25 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
AR072939A1 (es) * | 2008-08-20 | 2010-09-29 | Schering Corp | Derivados de piridina y pirimidina sustituidas con etenilo y su uso en el tratamiento de infecciones virales |
EP2331511A1 (en) * | 2008-08-20 | 2011-06-15 | Schering Corporation | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
EP2344201A1 (en) * | 2008-09-17 | 2011-07-20 | Nektar Therapeutics | Oligomer-protease inhibitor conjugates |
CN101744823B (zh) * | 2008-12-17 | 2013-06-19 | 广东东阳光药业有限公司 | 一种二氢嘧啶类化合物的固体分散体及其药用制剂 |
AU2010230344B9 (en) | 2009-03-30 | 2014-11-27 | Janssen Sciences Ireland Uc | Co-crystal of etravirine and nicotinamide |
EP2440051A4 (en) * | 2009-06-08 | 2012-12-19 | California Capital Equity Llc | TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS |
WO2010150279A2 (en) * | 2009-06-22 | 2010-12-29 | Emcure Pharmaceuticals Limited | Process for synthesis of diarylpyrimidine non-nucleoside reverse transcriptase inhibitor |
PT2576541T (pt) | 2010-06-04 | 2016-07-08 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
PT2638031T (pt) | 2010-11-10 | 2018-01-03 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de lrrk2 |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
EP2836517B1 (en) * | 2012-04-11 | 2016-07-27 | Dow Global Technologies LLC | Melt-extruded composition comprising a cellulose ether |
PT2836559T (pt) * | 2012-04-11 | 2016-08-31 | Dow Global Technologies Llc | Composição que compreende um diluente orgânico e um éter de celulose. |
BR112014020719B1 (pt) * | 2012-04-11 | 2020-03-03 | Dow Global Technologies Llc | Forma de dosagem de liberação constante, método para preparar uma forma de dosagem de liberação constante e uso de um éter de celulose |
EA036592B1 (ru) | 2012-06-13 | 2020-11-26 | Инсайт Холдингс Корпорейшн | Замещенные трициклические соединения как ингибиторы fgfr |
ES2664094T3 (es) * | 2012-07-12 | 2018-04-18 | Hetero Research Foundation | Procedimiento de preparación de rilpivirina utilizando un intermedio nuevo |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
WO2014172644A2 (en) | 2013-04-19 | 2014-10-23 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MX2021011472A (es) | 2015-01-06 | 2022-08-17 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
ES2895769T3 (es) | 2015-02-20 | 2022-02-22 | Incyte Corp | Heterociclos bicíclicos como inhibidores de FGFR |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
AR100459A1 (es) * | 2015-05-15 | 2016-10-05 | Química Luar S R L | Una composición farmacéutica antiviral de uso tópico |
US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
WO2018187652A1 (en) | 2017-04-06 | 2018-10-11 | Janssen Pharmaceutica Nv | 2,4-diaminopyrimidine derivatives as histamine h4 modulators |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CA3099287A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
CR20220169A (es) | 2019-10-14 | 2022-10-27 | Incyte Corp | Heterociclos bicíclicos como inhibidores de fgfr |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
AU2020391004A1 (en) | 2019-11-29 | 2022-04-07 | Aptorum Therapeutics Limited | Composition including rilpivirine and use thereof for treating tumors or cancer |
BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
KR102145925B1 (ko) | 2020-03-03 | 2020-08-19 | 협동조합 바이오융합기술 | 사포닌 성분이 함유된 항 바이러스용 조성물의 제조방법 |
CN111875548A (zh) * | 2020-07-16 | 2020-11-03 | 山东大学 | 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用 |
EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0270111A1 (en) * | 1986-12-03 | 1988-06-08 | Kumiai Chemical Industry Co., Ltd. | Pyrimidine derivatives and agricultural or horticultural fungicidal composition contaning the same |
EP0834507A1 (en) * | 1996-10-01 | 1998-04-08 | Janssen Pharmaceutica N.V. | Substituted diamino-1,3,5-triazine derivatives |
EP0872233A1 (en) * | 1997-04-14 | 1998-10-21 | Janssen Pharmaceutica N.V. | Antiretroviral compositions with improved bioavailability |
EP0945447A1 (en) * | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections |
EP0945443A1 (en) * | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | HIV inhibiting pyrimidine derivatives |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US230963A (en) | 1880-08-10 | John kobeetson | ||
US2742466A (en) | 1956-04-17 | Chx n nhx c c | ||
US2671810A (en) | 1952-05-24 | 1954-03-09 | Du Pont | Long-chain diketones |
US2748124A (en) | 1954-05-06 | 1956-05-29 | Searle & Co | 1-(4-anilino-2-pyrimidino)-3-alkylureas |
SU143808A1 (ru) | 1961-02-14 | 1961-11-30 | Н.В. Козлова | Способ получени 2-хлор-4,6-ди и 2,4,6-три-(2,4-дихлоранилин)-симм. триазинов |
GB1010998A (en) | 1962-10-09 | 1965-11-24 | British Petroleum Co | Pyrimidine derivatives |
US3478030A (en) | 1966-06-27 | 1969-11-11 | Abbott Lab | Benzamide substituted anilino aminopyrimidines |
BE754242A (fr) | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
DE2038182C3 (de) | 1970-07-31 | 1980-10-09 | Ciba-Geigy Ag, Basel (Schweiz) | 2-Substituierte 4,6-Diamino-stri azine |
GB1483271A (en) | 1975-03-22 | 1977-08-17 | Ciba Geigy Ag | Pigment complexes |
GB1477349A (en) | 1975-09-24 | 1977-06-22 | Ciba Geigy Ag | Azo pigments |
US4096206A (en) | 1976-02-09 | 1978-06-20 | Borg-Warner Corporation | Flame-retardant triazines |
FR2400535A1 (fr) | 1977-01-27 | 1979-03-16 | Borg Warner | Composition de polymere contenant des tris(haloarylamino)triazines ou des tris(haloarylthio)triazines fournissant une aptitude au retardement d'inflammation |
FR2398740A1 (fr) | 1978-11-06 | 1979-02-23 | Borg Warner | Compose fournissant une aptitude au retardement d'inflammation dans un polymere |
JPS57203072A (en) | 1981-06-05 | 1982-12-13 | Sankyo Co Ltd | 4-anilinopyrimidine derivative, its preparation, antidepressant comprising it as active ingredient |
US4659363A (en) | 1983-07-25 | 1987-04-21 | Ciba-Geigy Corporation | N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof |
US4652645A (en) | 1983-11-16 | 1987-03-24 | Ciba-Geigy Corporation | Cationic compounds |
US4694009A (en) | 1984-06-25 | 1987-09-15 | Ciba-Geigy Corporation | Pesticidal compositions |
DE68918804T2 (de) | 1988-03-31 | 1995-02-23 | Mitsubishi Chem Ind | Acyclische 6-substituierte pyrimidin nukleosid-abkömmlinge und antivirale mittel, die dieselben als aktive mittel enthalten. |
JPH0252360A (ja) | 1988-08-15 | 1990-02-21 | Fujitsu Ltd | 電子写真感光体 |
US4980371A (en) | 1988-12-21 | 1990-12-25 | Merrell Dow Pharmaceuticals | Antiretroviral furan ketones |
FI95376C (fi) | 1989-03-22 | 1996-01-25 | Ciba Geigy Ag | Mikrobisidiset 2-anilino-pyrimidiinijohdannaiset |
IE63502B1 (en) | 1989-04-21 | 1995-05-03 | Zeneca Ltd | Aminopyrimidine derivatives useful for treating cardiovascular disorders |
JPH02300264A (ja) | 1989-05-16 | 1990-12-12 | Fuji Photo Film Co Ltd | アミノピリミジンアゾメチン色素とその製造方法 |
JPH02308248A (ja) | 1989-05-24 | 1990-12-21 | Fuji Photo Film Co Ltd | アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料 |
US5064963A (en) | 1990-04-25 | 1991-11-12 | American Cyanamid Company | Process for the synthesis of n-(3-(1h-imidazol-1-yl)phenyl-4-(substituted)-2-pyrimidinamines |
GB9012592D0 (en) | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
IE75693B1 (en) | 1990-07-10 | 1997-09-10 | Janssen Pharmaceutica Nv | HIV-inhibiting benzeneacetamide derivatives |
JPH04159381A (ja) | 1990-10-23 | 1992-06-02 | Arakawa Chem Ind Co Ltd | ロジンエステルの製造方法 |
EP0541966A3 (en) | 1991-11-15 | 1994-09-07 | American Cyanamid Co | Process for preparing amide derivatives from halomines and acid halides |
US5283274A (en) | 1992-06-19 | 1994-02-01 | Uniroyal Chemical Company, Inc. | Substituted pyrimidines and substituted triazines as rubber-to-metal adhesion promoters |
IL106324A (en) | 1992-07-17 | 1998-09-24 | Shell Int Research | Transformed pyrimidine compounds, their preparation and use as pesticides |
US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
DE69418312D1 (de) | 1993-02-22 | 1999-06-10 | Janssen Pharmaceutica Nv | Aufheben der resistenz von hiv-1 linien gegenüber zidovudine |
WO1995010506A1 (en) * | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
PL313973A1 (en) | 1993-10-12 | 1996-08-05 | Du Pont Merck Pharma | 1 n-alkyl-n-arylopyrimidin amines and their derivatives |
GB9325217D0 (en) | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
DE19509807A1 (de) * | 1995-03-21 | 1996-09-26 | Basf Ag | Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen |
TW574214B (en) | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
IL114208A0 (en) | 1994-06-27 | 1995-10-31 | Merck & Co Inc | Combinations of compounds pharmaceutical compositions containing them and their use as hiv protease inhibitors |
TW401303B (en) | 1994-07-01 | 2000-08-11 | Janssen Pharmaceutica Nv | Anti-HIV triple combination |
US5574040A (en) | 1995-01-06 | 1996-11-12 | Picower Institute For Medical Research | Pyrimidine compounds and methods of use to derivatize neighboring lysine residues in proteins under physiologic conditions |
JP3691101B2 (ja) | 1995-01-24 | 2005-08-31 | 三洋電機株式会社 | 有機エレクトロルミネッセンス素子 |
DE19504832A1 (de) * | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
US5691364A (en) | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
JPH09101590A (ja) | 1995-07-28 | 1997-04-15 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料およびその包装体 |
US5837436A (en) | 1995-07-28 | 1998-11-17 | Fuji Photo Film Co., Ltd. | Silver halide color photographic material and package thereof |
JPH0968784A (ja) | 1995-08-31 | 1997-03-11 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
JPH0980676A (ja) | 1995-09-13 | 1997-03-28 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料およびその包装体 |
GB9519197D0 (en) | 1995-09-20 | 1995-11-22 | Affinity Chromatography Ltd | Novel affinity ligands and their use |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
CN1163401A (zh) | 1996-02-13 | 1997-10-29 | 李占元 | 全自动血球计数仪试剂及配制方法 |
GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
JPH11116555A (ja) | 1997-10-14 | 1999-04-27 | Ube Ind Ltd | 4−アニリノピリミジン誘導体及びそれを有効成分とする農園芸用の殺虫・殺ダニ・殺菌剤 |
KR20010041015A (ko) | 1998-02-17 | 2001-05-15 | 윌리엄 제이. 리플린 | 항바이러스성 피리미딘 유도체 |
EP0945442A1 (en) | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted pyrimidine derivatives |
KR100643419B1 (ko) * | 1998-03-27 | 2006-11-10 | 얀센 파마슈티카 엔.브이. | Hiv를 억제하는 피리미딘 유도체 |
JP2000111191A (ja) | 1998-08-04 | 2000-04-18 | Tokyo Gas Co Ltd | 吸収冷温水機 |
SK287270B6 (sk) | 1998-11-10 | 2010-05-07 | Janssen Pharmaceutica N. V. | Derivát pyrimidínu |
US6876717B1 (en) * | 2004-08-19 | 2005-04-05 | Intel Corporation | Multi-stage programmable Johnson counter |
-
2000
- 2000-08-31 NZ NZ517025A patent/NZ517025A/en not_active IP Right Cessation
- 2000-08-31 AP APAP/P/2002/002482A patent/AP1639A/en active
- 2000-08-31 TR TR2002/00763T patent/TR200200763T2/xx unknown
- 2000-08-31 EE EEP200200151A patent/EE04991B1/xx unknown
- 2000-08-31 CZ CZ20020907A patent/CZ300712B6/cs not_active IP Right Cessation
- 2000-08-31 CA CA002384188A patent/CA2384188C/en not_active Expired - Lifetime
- 2000-08-31 BR BRPI0014271-9A patent/BRPI0014271B1/pt not_active IP Right Cessation
- 2000-08-31 WO PCT/EP2000/008522 patent/WO2001022938A1/en active IP Right Grant
- 2000-08-31 KR KR1020027002218A patent/KR100785360B1/ko active IP Right Grant
- 2000-08-31 DK DK00964080T patent/DK1225874T3/da active
- 2000-08-31 DE DE60025837T patent/DE60025837T2/de not_active Expired - Lifetime
- 2000-08-31 JP JP2001526150A patent/JP4919566B2/ja not_active Expired - Lifetime
- 2000-08-31 SK SK376-2002A patent/SK285240B6/sk not_active IP Right Cessation
- 2000-08-31 HU HU0203568A patent/HU228449B1/hu unknown
- 2000-08-31 UA UA2002043289A patent/UA74797C2/uk unknown
- 2000-08-31 SI SI200030842T patent/SI1225874T1/sl unknown
- 2000-08-31 AT AT00964080T patent/ATE316781T1/de active
- 2000-08-31 EA EA200200401A patent/EA005423B1/ru not_active IP Right Cessation
- 2000-08-31 PT PT00964080T patent/PT1225874E/pt unknown
- 2000-08-31 OA OA1200200085A patent/OA12029A/en unknown
- 2000-08-31 IL IL14880100A patent/IL148801A0/xx active IP Right Grant
- 2000-08-31 KR KR1020077006306A patent/KR100820605B1/ko active IP Right Grant
- 2000-08-31 EP EP00964080A patent/EP1225874B1/en not_active Expired - Lifetime
- 2000-08-31 CN CNB008133212A patent/CN1234347C/zh not_active Expired - Lifetime
- 2000-08-31 PL PL354026A patent/PL207590B1/pl unknown
- 2000-08-31 MX MXPA02003182A patent/MXPA02003182A/es active IP Right Grant
- 2000-08-31 ES ES00964080T patent/ES2258018T3/es not_active Expired - Lifetime
- 2000-08-31 AU AU75127/00A patent/AU775360B2/en not_active Revoked
- 2000-08-31 US US10/088,805 patent/US7241458B1/en not_active Expired - Lifetime
-
2002
- 2002-01-31 IS IS6256A patent/IS2567B/is unknown
- 2002-03-14 BG BG106521A patent/BG65754B1/bg unknown
- 2002-03-20 ZA ZA200202289A patent/ZA200202289B/en unknown
- 2002-03-22 HR HR20020247A patent/HRP20020247B1/xx not_active IP Right Cessation
- 2002-03-22 NO NO20021443A patent/NO333358B1/no not_active IP Right Cessation
-
2003
- 2003-02-11 HK HK03100992.5A patent/HK1048768B/zh not_active IP Right Cessation
-
2004
- 2004-10-29 AU AU2004224973A patent/AU2004224973C1/en not_active Expired
-
2006
- 2006-02-03 US US11/347,071 patent/US7887845B2/en not_active Expired - Lifetime
- 2006-04-28 CY CY20061100557T patent/CY1105268T1/el unknown
-
2007
- 2007-04-10 US US11/733,507 patent/US20070196478A1/en not_active Abandoned
-
2010
- 2010-03-16 US US12/724,566 patent/US20100172970A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0270111A1 (en) * | 1986-12-03 | 1988-06-08 | Kumiai Chemical Industry Co., Ltd. | Pyrimidine derivatives and agricultural or horticultural fungicidal composition contaning the same |
EP0834507A1 (en) * | 1996-10-01 | 1998-04-08 | Janssen Pharmaceutica N.V. | Substituted diamino-1,3,5-triazine derivatives |
EP0872233A1 (en) * | 1997-04-14 | 1998-10-21 | Janssen Pharmaceutica N.V. | Antiretroviral compositions with improved bioavailability |
EP0945447A1 (en) * | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections |
EP0945443A1 (en) * | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | HIV inhibiting pyrimidine derivatives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20020247B1 (en) | Antiviral compositions | |
HRP20000620B1 (en) | Hiv inhibiting pyrimidine derivatives | |
HRP20030624B1 (en) | 6-substituted pyrido-pyrimidines | |
PA8607001A1 (es) | Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3 | |
HRP20080184T3 (en) | Novel azabicyclic derivatives, preparation method thereof and pharmaceutical compositions containing same | |
RS51007B (sr) | Supstituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga | |
RS51743B (en) | MACROCYCLIC HEPATITIS VIRUS INHIBITORS C | |
AR018169A1 (es) | Uso de compuestos derivados trisustituidos de 1,3,5-triazina para la elaboracion de un medicamento, compuestos derivados de los mismos, un procesopara su preparacion, una composicion farmaceutica que los comprende, un proceso para su preparacion, la combinacion de los mismos con un compuesto antiret | |
ATE346111T1 (de) | S-kristalline polypropylene | |
AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
NZ324007A (en) | Quinazoline derivatives susbtituted by a phenyl and medicaments | |
AR017217A1 (es) | Compuestos antiarritmicos de bispidina, formulacion farmaceutica, uso de los mismos para preparar medicamentos, proceso para preparar dichos compuestos,compuestos intermediarios, y proceso para prepararlos | |
AR045687A1 (es) | Macrociclos derivados de la quinazolina, procesos de preparacion y composiciones farmaceuticas que los contienen | |
IL128690A0 (en) | Cyclic amine derivatives pharmaceutical compositions containing the same and use thereof | |
MX2008008850A (es) | Composiciones para el cuidado personal que contienen copolimeros cationicos sinteticos y un surfactante detergente. | |
AR020154A1 (es) | Derivados de glicol de xantinas, composiciones farmaceuticas, uso en la manufactura de medicamentos, metodos de tratamiento y proceso de preparacion | |
AR054484A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
GEP20074209B (en) | Multi-substitued selective androgen receptor modulators and methods of use thereof | |
JO2652B1 (en) | Compounds 5,4,2,1 Tetra Hydro-H3-benzazepine Method of preparation and pharmaceutical compounds containing | |
MX271169B (es) | Derivados de hidroxifenil-benzofenona sustituidos con amino. | |
MY111368A (en) | Pharmaceutical compounds. | |
IL163625A0 (en) | Alkoxy-pyridine derivatives and pharmaceutical compositions containing the same | |
CA2130344A1 (en) | Triazine derivates with uv-filter properties | |
AR035820A1 (es) | Derivados de 1,3,8-triazaspiro[4,5]decan-4-ona, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparación de medicamentos | |
DK0915915T3 (da) | Vandopløselige polymerisater og deres anvendelse i kosmetiske sammensætninger |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20190715 Year of fee payment: 20 |
|
PB20 | Patent expired after termination of 20 years |
Effective date: 20200831 |